Tissue and subcellular distribution of enzymes inactivating leupeptin

Preparation and purification of the proteinase inhibitor, leupeptin, from culture filtrates of Streptomyces lavendulae

Leupeptin (N-acetyl-L-leucyl-L-leucyl-L-argininal) was produced as an extracellular metabolite by Streptomyces lavendulae. Addition of lysine to the growth medium stimulated leupeptin production from 200 to 1400 micrograms/ml. Incubation of late exponential phase mycelium in a synthetic medium was used to prepare single labelled (3H) and double labelled (3H/14C) inhibitor for metabolic studies. An improved purification scheme that generates leupeptin of high purity with good recoveries is also reported.

Metabolism of [3H]leupeptin by rat liver

Tritium-labeled leupeptin was used to study how this tripeptide proteinase inhibitor interacts with the liver, including the mechanism of its transport into the cell, its subcellular distribution after uptake, and its metabolism once in the tissue. Experiments were done in situ and in a perfused liver. At low concentrations (1 to 10 microM) the uptake of radioactive inhibitor was competed by chemically reduced leupeptin. At high concentrations at least up to 400 microM the uptake was directly proportional to the external concentration of tripeptide. Entry into the tissue essentially stopped at low temperature (less than 21 degrees C). [3H]Leupeptin initially was located in the soluble fraction of the liver homogenate and by 15 to 30 min became concentrated in the lysosome-rich fraction. During 2 h of perfusion almost 50% of [3H]leupeptin that had entered the liver was secreted intact into the bile. In addition, a portion of the leupeptin that remained in the liver was degraded during this time period.

[Action of proteinase inhibitors. 4. Effect of short-term application of chymostatin on nitrogen metabolism in the digestive tract and protein metabolism in tissue]

Chymostatin is an effective inhibitor of intracellular proteinases in vitro. In the present experiment male rats were injected intraperitonealy during a 3 days period twice daily with a solution containing 0,9 mg Chymostatin per 100 g live weight. Reference animals received a control injection containing the same solvents but no chymostatin. During this period a daily nitrogen balance was made and metabolic faecal nitrogen and true digestibility of nitrogen were estimated using 15N-labelled animals. Furthermore, apparent biological half lives of proteins in liver and intestinal tissues were determined following the decay curves for radioactivity in proteins 48 hours after injection of L-[5-3H]-arginine und L-[guanido-14C]-arginine. The fractional rate of protein synthesis in tissues was measured by a 6 hours continuous infusion technique with L-[U-14C]-tyrosine and L-[U-14C]-leucine. Among the parameters estimated only the apparent biological half lives of proteins in liver and intestinal tissues were influenced by chymostatin. However, the prolonged half lives seemed to be rather an effect of an increased reutilisation of amino acids resulting from the intracellular protein breakdown than a decreased rate of protein degradation. The in vivo effect of the proteinase inhibitor was by far inferior compared with the action in vitro. Factors like distribution, degradation and excretion of the inhibitor could be responsible for the moderate in vivo action of chymostatin.